BCYC — Bicycle Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $1.75bn
- $822.67m
- $26.98m
- 41
- 17
- 56
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13.8 | 10.4 | 11.7 | 14.5 | 27 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 40.1 | 62.4 | 77.3 | 131 | 217 |
Operating Profit | -26.3 | -52 | -65.6 | -117 | -190 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -30.9 | -51.7 | -68.5 | -114 | -179 |
Provision for Income Taxes | |||||
Net Income After Taxes | -30.6 | -51 | -66.8 | -113 | -181 |
Net Income Before Extraordinary Items | |||||
Net Income | -30.6 | -51 | -66.8 | -113 | -181 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -30.6 | -51 | -66.8 | -113 | -181 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.77 | -2.66 | -2.67 | -3.8 | -5.08 |